SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...
MASP-2 is the effector enzyme of the lectin pathway, one of the principal complement activation pathways. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...
The treatment landscape for C3G has historically depended on the off-label use of multiple prescription therapies, ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Novo Nordisk logo is seen in this illustration created on August 5, 2025. REUTERS/Dado Ruvic/Illustration/File Photo ...
The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...
The complement system represents a cornerstone of innate immunity, comprising a cascade of plasma proteins that, upon activation, facilitate pathogen clearance and coordinate inflammatory signalling.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results